OMEPRAZOLE EXTENDED-RELEASE CAPSULES

The Defense Logistics Agency awarded Contract SPE2DP26F7671 to DMS PHARMACEUTICAL GROUP INC under the parent delivery order SPE2DX25D9900 for the procurement of four units of OMEPRAZOLE EXTENDED-RELEASE CAPSULES, identified by NSN 6505013142716, at a unit price of $43.60 for a total value of $174.40. The award was issued on July 14, 2026, with delivery required to the destination address at Fort Lewis, Washington under FOB destination terms, meaning the contractor bears all freight charges and assumes responsibility for timely and traceable shipment, explicitly prohibiting parcel post. Inspection and acceptance are performed by the government at the delivery point, with zero tolerance for quantity variance. The item is governed by medical substitution protocol RANK 01 and aligns with DLA’s pharmaceutical supply standards. Packaging and labeling specifications are not detailed in the contract, though standard DoD identifiers including CAGE code 1UNB0, DIC A0A, and funding code Z9 are referenced. Payment is processed through the designated military finance office in Fort Lewis, with invoicing likely submitted via WAWF. No explicit FAR clauses, special requirements, evaluation factors, or certification statements are documented within the provided text, and no MIL-STD packaging standards are cited. The NAICS code 424210 indicates a pharmaceutical and medical supplies wholesaler classification, but no socioeconomic status or small business certifications are confirmed. The award is structured as a simple, low-value delivery order with no options, modifications, or extended performance periods, indicating a routine procurement based on established medical supply needs.